Evaluation of Isoniazid 300 mg Drug for the Treatment of Latent Tuberculosis Infection in Brazil
Not Applicable
- Conditions
- atent TuberculosisC01.252.410.040.552.846.122
- Registration Number
- RBR-8wjq29
- Lead Sponsor
- niversidade Federal do Espirito Santo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who agree with the consent form; Patients of both sexes; Indication for treatment with isoniazid 300mg per day; With access to mobile smartphone with Android operating system; patients who know or not read; age between 18 and 50 years;
Exclusion Criteria
Patients on treatment for rifampicin or already on treatment for latent tuberculosis; patients with HIV; pregnant or intending to become pregnant; homeless patients; deprived of liberty; Patients referred for treatment over 6 months.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method